{"id":"NCT01062763","sponsor":"Ib Abildgaard Jacobsen","briefTitle":"The Effect of Spironolactone on Blood Pressure in Type-2 Diabetics With Resistant Hypertension","officialTitle":"South Danish Hypertension and Diabetes Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-03","primaryCompletion":"2012-03","completion":"2012-05","firstPosted":"2010-02-04","resultsPosted":"2014-05-08","lastUpdate":"2014-05-08"},"enrollment":119,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Arterial Hypertension","Hypertension, Resistant to Conventional Therapy","Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"spironolactone","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"addition of spironolactone","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to estimate the effect of spironolactone on blood pressure resistant to therapy in type-2 diabetics.","primaryOutcome":{"measure":"Change of of Systolic Blood Pressure","timeFrame":"4 months","effectByArm":[{"arm":"Addition of Spironolactone","deltaMin":-9.6,"sd":null},{"arm":"Placebo","deltaMin":-0.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":11},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["11821720","14573330","16814132","17309946","33107592","24739800"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":61},"commonTop":[]}}